stockrowAtriCure, Inc.
ATRC Healthcare Medical Instruments & Supplies
AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024.
- Revenue
- +15.0%
- EPS
- +1,583.9%
- Free cash flow
- −0.73%
- Total debt
- −17.3%
Quarter to September 2026, against a year earlier
Follow ATRC
Alert me
AtriCure, Inc. (ATRC) EPS (diluted)
AtriCure, Inc.'s EPS (diluted) for fiscal 2025 was −$0.24, compared with −$0.95 in fiscal 2024. Over the twelve months to 30 September 2026 it was $0.30. Over the past ten years it has ranged from −$1.14 (fiscal 2020) to $1.09 (fiscal 2021); the current reading is higher than 91% of that period. AtriCure, Inc. ranks 21st of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.24 | — |
| FY2024 | −$0.95 | — |
| FY2023 | −$0.66 | — |
| FY2022 | −$1.02 | — |
| FY2021 | $1.09 | — |
| FY2020 | −$1.14 | — |
| FY2019 | −$0.94 | — |
| FY2018 | −$0.62 | — |
| FY2017 | −$0.83 | — |
| FY2016 | −$1.05 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.08 | (54.67%) |
| Jun 2026 | $0.18 | 8,081.82% |
| Mar 2026 | $0.00 | (94.50%) |
| Dec 2025 | $0.04 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| NVST Envista Holdings Corporation compare | $3.92 |
| MMSI Merit Medical Systems, Inc. compare | $2.66 |
| ICUI ICU Medical, Inc. compare | $2.39 |
| STVN Stevanato Group S.p.A. compare | $0.59 |
| ATRC AtriCure, Inc. | $0.30 |
| WRBY Warby Parker Inc. compare | $0.06 |
| MMED MiniMed Group, Inc. compare | −$0.59 |
| XRAY DENTSPLY SIRONA Inc. compare | −$0.62 |
| PLSE Pulse Biosciences, Inc compare | −$1.21 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ATRC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement